D.M. (Daniël) Miedema

Dr. D.M. (Daniël) Miedema

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
EDErik van Dijk
Erik van Dijk
TBTom van Den Bosch
Tom van Den Bosch
KLKristiaan J. Lenos
Kristiaan J. Lenos
KMKhalid El Makrini
Khalid El Makrini
LNLisanne E. Nijman
Lisanne E. Nijman
DMD.M. (Daniël) Miedema
D.M. (Daniël) Miedema
Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrations are at the root of all cancers, individual genomic features cannot explain these distinct disease outcomes. In contrast, intra-tumour heterogeneity (ITH) has the potential to elucidate pan-cancer survival rates and the biology that drives cancer prognosis. Unfortunately, a comprehensive and effective framework to measure ITH across cancers is missing. Here, we introduce a scalable measure of chromosomal copy number heterogeneity (CNH) that predicts patient survival across cancers. We show that the level of ITH can be derived from a single-sample copy number profile. Using gene-expression data and live cell imaging we demonstrate that ongoing chromosomal instability underlies the observed heterogeneity. Analysing 11,534 primary cancer samples from 37 different malignancies, we find that copy number heterogeneity can be accurately deduced and predicts cancer survival across tissues of origin and stages of disease. Our results provide a unifying molecular explanation for the different survival rates observed between cancer types.

1 April 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TBTom van Den Bosch
Tom van Den Bosch
AWAnne-Loes K. Warps
Anne-Loes K. Warps
MBMichael P. M. de Nerée Tot Babberich
Michael P. M. de Nerée Tot Babberich
CSChristina Stamm
Christina Stamm
BGBart F. Geerts
Bart F. Geerts
DADutch ColoRectal Audit
Dutch ColoRectal Audit
Resection of colorectal cancer is a frequently performed surgical procedure with a generally reported incidence of complications of more than 30%,1 and these complications are associated with patient burden and increased health care use.2,3 A European study showed that nearly one-third of hospital budgets are spent on treating complications of colorectal cancer surgery.4 Identifying patients at risk for complications is thus of significant importance. Previously identified risk factors for postoperative complications are advanced age, higher American Society of Anesthesiology (ASA) score, emergency surgery, comorbidities, and advanced tumor stage.1,5-11

17 December 2020 in Blood
Verified
Journal Article
Closed access
PDF file
GVG. Tjitske Los-De Vries
G. Tjitske Los-De Vries
MBMintsje de Boer
Mintsje de Boer
EDErik van Dijk
Erik van Dijk
PSPhylicia Stathi
Phylicia Stathi
NHNathalie J. Hijmering
Nathalie J. Hijmering
Daphne D. De JongDaphne D. De Jong
Daphne D. De Jong
Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a very rare type of T-cell lymphoma that is uniquely caused by a single environmental stimulus. Here, we present a comprehensive genetic analysis of a relatively large series of BIA-ALCL (n = 29), for which genome-wide chromosomal copy number aberrations (CNAs) and mutational profiles for a subset (n = 7) were determined. For comparison, CNAs for anaplastic lymphoma kinase (ALK)− nodal anaplastic large cell lymphomas (ALCLs; n = 24) were obtained. CNAs were detected in 94% of BIA-ALCLs, with losses at chromosome 20q13.13 in 66% of the samples. Loss of 20q13.13 is characteristic of BIA-ALCL compared with other classes of ALCL, such as primary cutaneous ALCL and systemic type ALK+ and ALK− ALCL. Mutational patterns confirm that the interleukin-6–JAK1–STAT3 pathway is deregulated. Although this is commonly observed across various types of T-cell lymphomas, the extent of deregulation is significantly higher in BIA-ALCL, as indicated by phosphorylated STAT3 immunohistochemistry. The characteristic loss of chromosome 20 in BIA-ALCL provides further justification to recognize BIA-ALCL as a separate disease entity. Moreover, CNA analysis may serve as a parameter for future diagnostic assays for women with breast implants to distinguish seroma caused by BIA-ALCL from other causes of seroma accumulation, such as infection or trauma.

12 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TBTom van Den Bosch
Tom van Den Bosch
SDSarah Derks
Sarah Derks
DMD.M. (Daniël) Miedema
D.M. (Daniël) Miedema
Intra-tumor heterogeneity (ITH) is a pan-cancer predictor of survival, with high ITH being correlated to a dismal prognosis. The level of ITH is, hence, a clinically relevant characteristic of a malignancy. ITH of karyotypes is driven by chromosomal instability (CIN). However, not all new karyotypes generated by CIN are viable or competitive, which limits the amount of ITH. Here, we review the cellular processes and ecological properties that determine karyotype ITH. We propose a framework to understand karyotype ITH, in which cells with new karyotypes emerge through CIN, are selected by cell intrinsic and cell extrinsic selective pressures, and propagate through a cancer in competition with other malignant cells. We further discuss how CIN modulates the cell phenotype and immune microenvironment, and the implications this has for the subsequent selection of karyotypes. Together, we aim to provide a comprehensive overview of the biological processes that shape the level of karyotype heterogeneity.

16 August 2019 in Nature Protocols
Verified
Journal Article
Closed access
KLKristiaan J. Lenos
Kristiaan J. Lenos
SLSophie C. Lodestijn
Sophie C. Lodestijn
SLScott K. Lyons
Scott K. Lyons
MBMaarten F. Bijlsma
Maarten F. Bijlsma
DMD.M. (Daniël) Miedema
D.M. (Daniël) Miedema
LVLouis Vermeulen
Louis Vermeulen

8 June 2022 in Computational and Systems Oncology
Verified
Journal Article
Open access
TBTom van Den Bosch
Tom van Den Bosch
LVLouis Vermeulen
Louis Vermeulen
DMD.M. (Daniël) Miedema
D.M. (Daniël) Miedema
Intratumor heterogeneity (ITH) is an omnipresent property of cancers and predicts poor survival in most types of cancer. The propensity to metastasize and the regrowth of tumors after therapy are both associated with ITH. Quantification of the level of ITH in a malignancy is hence of great interest, and accurate inference of ITH could guide clinical decision making. However, ITH is an emergent property of billions of cells and requires mathematical modeling for inference from a limited number of measurements. Over the last decade, numerous mathematical and computational models have been introduced to infer ITH from variant‐allele frequencies, copy number variations, or from data of experimental model systems. These quantitative modeling efforts have advanced the understanding of tumor evolution, underlined poor prognosis associated with ITH, and elucidated the importance of functional heterogeneity, that is, cancer stem cells. Yet, a comprehensive overview of the different mathematical models, their underlying assumptions, their limitations, and their strengths is missing. In this Perspective, we highlight the achievements of mathematical modeling and present a framework which allows better understanding of the mathematical models themselves.